Skip to main content
Fig. 1 | Cardiovascular Diabetology

Fig. 1

From: Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND

Fig. 1

Effects of treatment on potential mediators over time up to 6 years: dulaglutide versus placebo. Dulaglutide significantly reduced HbA1c, body weight, WHR, SBP, LDL, and UACR over time from baseline compared to placebo. HbA1c hemoglobin A1c, LDL low density lipoprotein, LSM least squares mean, SBP systolic blood pressure, SE standard error, UACR urine albumin creatinine ratio, WHR waist-to-hip ratio

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840